A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-04

AUTHORS

Srikala S. Sridhar, Christina M. Canil, Kim N. Chi, Sebastien J. Hotte, Scott Ernst, Lisa Wang, Eric X. Chen, Agnes Juhasz, Yun Yen, Peter Murray, James A. Zwiebel, Malcolm J. Moore

ABSTRACT

PURPOSE: GTI-2040 is a novel antisense oligonucleotide to the R2 subunit of ribonucleotide reductase. This phase II trial was conducted to determine the efficacy and tolerability of GTI-2040 when combined with docetaxel and prednisone for the treatment of patients with castration-resistant prostate cancer (CRPC). METHODS: Chemo-naïve CRPC patients with adequate performance status and organ function were treated with docetaxel 75 mg/m(2) IV on day 1 plus GTI-2040 5 mg/kg/day by continuous intravenous infusion day 1-14 on a 21 day cycle, with prednisone 5 mg orally twice daily. The primary endpoint was PSA response rate. Pharmacokinetic studies of GTI-2040 and pharmacodynamic studies on peripheral blood mononuclear cells (PBMC) were also performed. RESULTS: Twenty-two patients in total (19 from this study and 3 from a prior phase I/II study at this institution) were treated at the recommended phase II dose. A confirmed PSA response was seen in 9/22 patients (41%). Of 16 patients with measurable disease, there was 1 partial response (PR) and 12 stable disease (SD) lasting 3.6 months (median), as best response. The most common toxicities were anemia, fatigue, lymphopenia, leucopenia and neutropenia. Grade 3+ toxicities included neutropenia, lymphopenia, leucopenia, fatigue, febrile neutropenia and hypophosphatemia. CONCLUSIONS: The PSA response rate of GTI-2040 in combination with docetaxel and prednisone just met the minimum phase II criteria for further enrollment. However, after evaluation of all the clinical data, further study of this dose and schedule of GTI-2040 in CRPC was not recommended. More... »

PAGES

927-933

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-010-1389-7

DOI

http://dx.doi.org/10.1007/s00280-010-1389-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028116130

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20602233


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukocytes, Mononuclear", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligodeoxyribonucleotides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Orchiectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sridhar", 
        "givenName": "Srikala S.", 
        "id": "sg:person.01204166657.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204166657.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Ottawa Regional Cancer Centre, Ottawa, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Canil", 
        "givenName": "Christina M.", 
        "id": "sg:person.0617500177.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617500177.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "BC Cancer Agency, Vancouver, BC, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chi", 
        "givenName": "Kim N.", 
        "id": "sg:person.01142252161.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Juravinski Cancer Center, Hamilton, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hotte", 
        "givenName": "Sebastien J.", 
        "id": "sg:person.01116377030.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116377030.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "London Regional Cancer Center, London, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ernst", 
        "givenName": "Scott", 
        "id": "sg:person.01236307062.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236307062.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Lisa", 
        "id": "sg:person.012667465007.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012667465007.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Eric X.", 
        "id": "sg:person.0754450325.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754450325.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "City Of Hope National Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "City of Hope National Medical Centre, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Juhasz", 
        "givenName": "Agnes", 
        "id": "sg:person.01007474330.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007474330.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "City Of Hope National Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "City of Hope National Medical Centre, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yen", 
        "givenName": "Yun", 
        "id": "sg:person.0760103773.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760103773.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Lorus Therapeutics Inc, Toronto, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Murray", 
        "givenName": "Peter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zwiebel", 
        "givenName": "James A.", 
        "id": "sg:person.01123742514.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123742514.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moore", 
        "givenName": "Malcolm J.", 
        "id": "sg:person.07455026572.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07455026572.07"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-07-0944", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006922944"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1163-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011933531", 
          "https://doi.org/10.1007/s00280-009-1163-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1163-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011933531", 
          "https://doi.org/10.1007/s00280-009-1163-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1163-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011933531", 
          "https://doi.org/10.1007/s00280-009-1163-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jchromb.2005.09.036", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015047150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa041318", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028543233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa040720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029249997"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0109", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031820808"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050255200"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0197-2456(89)90015-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053744925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/bi00475a007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055177617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008332724977", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.15.5.1299", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071530002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.11.3461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074545753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075013035", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075295406", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077265246", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.23.16_suppl.7253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079368204"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083167129", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083251660", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.18_suppl.lba4511", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083946811"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1115/icem2007-7291", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092859094"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-04", 
    "datePublishedReg": "2011-04-01", 
    "description": "PURPOSE: GTI-2040 is a novel antisense oligonucleotide to the R2 subunit of ribonucleotide reductase. This phase II trial was conducted to determine the efficacy and tolerability of GTI-2040 when combined with docetaxel and prednisone for the treatment of patients with castration-resistant prostate cancer (CRPC).\nMETHODS: Chemo-na\u00efve CRPC patients with adequate performance status and organ function were treated with docetaxel 75 mg/m(2) IV on day 1 plus GTI-2040 5 mg/kg/day by continuous intravenous infusion day 1-14 on a 21 day cycle, with prednisone 5 mg orally twice daily. The primary endpoint was PSA response rate. Pharmacokinetic studies of GTI-2040 and pharmacodynamic studies on peripheral blood mononuclear cells (PBMC) were also performed.\nRESULTS: Twenty-two patients in total (19 from this study and 3 from a prior phase I/II study at this institution) were treated at the recommended phase II dose. A confirmed PSA response was seen in 9/22 patients (41%). Of 16 patients with measurable disease, there was 1 partial response (PR) and 12 stable disease (SD) lasting 3.6 months (median), as best response. The most common toxicities were anemia, fatigue, lymphopenia, leucopenia and neutropenia. Grade 3+ toxicities included neutropenia, lymphopenia, leucopenia, fatigue, febrile neutropenia and hypophosphatemia.\nCONCLUSIONS: The PSA response rate of GTI-2040 in combination with docetaxel and prednisone just met the minimum phase II criteria for further enrollment. However, after evaluation of all the clinical data, further study of this dose and schedule of GTI-2040 in CRPC was not recommended.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-010-1389-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2426791", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "67"
      }
    ], 
    "name": "A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer", 
    "pagination": "927-933", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "85f03debb1265c2f8da6fcd723e1099d1b7df7557bce34ae0cbd597612af2b90"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20602233"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-010-1389-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028116130"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-010-1389-7", 
      "https://app.dimensions.ai/details/publication/pub.1028116130"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-010-1389-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1389-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1389-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1389-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1389-7'


 

This table displays all metadata directly associated to this object as RDF triples.

283 TRIPLES      21 PREDICATES      64 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-010-1389-7 schema:about N104f09d30db1453a958f2b4ecc6fb2ed
2 N16a41c30b7164820b87e5db013f8631e
3 N2b62b4d0b1b54b66b361003f98b4cfa1
4 N31c1385c33094776a9c1034e70c1e532
5 N37b8091e8e5e4308aecf961b3ad2acaf
6 N8074b3cab8a3481f934733ce7cb45db6
7 N820f16b9507b4f2b886e98797f4ca5a9
8 N854763b9cc304424be726418ccac7040
9 N8661d8c25d004bfca582457f3bf92ee0
10 N8d7242c954654bb3af756e5ed1cc51b7
11 Nbad64eea7d8340d4994bb9db00891324
12 Nbc7eb85bcd4e4e6ba177e81d713263e0
13 Ne3964dcac4f744c895f1a8d33ffc2d29
14 Ne9bfdfc08bda4bc4be6b9b759eec0634
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N8b84f79f49ee44939c125df754ded6dd
18 schema:citation sg:pub.10.1007/s00280-009-1163-x
19 https://app.dimensions.ai/details/publication/pub.1075013035
20 https://app.dimensions.ai/details/publication/pub.1075295406
21 https://app.dimensions.ai/details/publication/pub.1077265246
22 https://app.dimensions.ai/details/publication/pub.1083167129
23 https://app.dimensions.ai/details/publication/pub.1083251660
24 https://doi.org/10.1016/0197-2456(89)90015-9
25 https://doi.org/10.1016/j.jchromb.2005.09.036
26 https://doi.org/10.1021/bi00475a007
27 https://doi.org/10.1023/a:1008332724977
28 https://doi.org/10.1056/nejmoa040720
29 https://doi.org/10.1056/nejmoa041318
30 https://doi.org/10.1093/annonc/mdi178
31 https://doi.org/10.1093/jnci/92.3.205
32 https://doi.org/10.1115/icem2007-7291
33 https://doi.org/10.1158/1078-0432.ccr-07-0944
34 https://doi.org/10.1158/1078-0432.ccr-08-0109
35 https://doi.org/10.1200/jco.1999.17.11.3461
36 https://doi.org/10.1200/jco.2005.23.16_suppl.7253
37 https://doi.org/10.1200/jco.2010.28.18_suppl.lba4511
38 https://doi.org/10.3892/or.15.5.1299
39 schema:datePublished 2011-04
40 schema:datePublishedReg 2011-04-01
41 schema:description PURPOSE: GTI-2040 is a novel antisense oligonucleotide to the R2 subunit of ribonucleotide reductase. This phase II trial was conducted to determine the efficacy and tolerability of GTI-2040 when combined with docetaxel and prednisone for the treatment of patients with castration-resistant prostate cancer (CRPC). METHODS: Chemo-naïve CRPC patients with adequate performance status and organ function were treated with docetaxel 75 mg/m(2) IV on day 1 plus GTI-2040 5 mg/kg/day by continuous intravenous infusion day 1-14 on a 21 day cycle, with prednisone 5 mg orally twice daily. The primary endpoint was PSA response rate. Pharmacokinetic studies of GTI-2040 and pharmacodynamic studies on peripheral blood mononuclear cells (PBMC) were also performed. RESULTS: Twenty-two patients in total (19 from this study and 3 from a prior phase I/II study at this institution) were treated at the recommended phase II dose. A confirmed PSA response was seen in 9/22 patients (41%). Of 16 patients with measurable disease, there was 1 partial response (PR) and 12 stable disease (SD) lasting 3.6 months (median), as best response. The most common toxicities were anemia, fatigue, lymphopenia, leucopenia and neutropenia. Grade 3+ toxicities included neutropenia, lymphopenia, leucopenia, fatigue, febrile neutropenia and hypophosphatemia. CONCLUSIONS: The PSA response rate of GTI-2040 in combination with docetaxel and prednisone just met the minimum phase II criteria for further enrollment. However, after evaluation of all the clinical data, further study of this dose and schedule of GTI-2040 in CRPC was not recommended.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree false
45 schema:isPartOf N2ffab99e33474f7a8e08f5ca3c8af3c1
46 N5fc0afc42ca8459f900dfc2dd89d95a2
47 sg:journal.1088364
48 schema:name A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
49 schema:pagination 927-933
50 schema:productId N3a63e465457d4f5e8ea49044cc1ea483
51 N6f89a799be0c4836bc33b3e997af5f7b
52 N7963cd531f7140219759201feee4ca9a
53 Na2690eaec180498dba2e1b665df52e7c
54 Nb6db3871916844988f2f47be19bfd2d2
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028116130
56 https://doi.org/10.1007/s00280-010-1389-7
57 schema:sdDatePublished 2019-04-10T17:32
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher N0a70005f85b8407b918204c6c5cc0d7d
60 schema:url http://link.springer.com/10.1007%2Fs00280-010-1389-7
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N08b8a65e9b5943e4ab202624cc7c86a1 schema:affiliation N1216ff731e1f4f8ab541aae667c4cf5d
65 schema:familyName Murray
66 schema:givenName Peter
67 rdf:type schema:Person
68 N0a70005f85b8407b918204c6c5cc0d7d schema:name Springer Nature - SN SciGraph project
69 rdf:type schema:Organization
70 N104f09d30db1453a958f2b4ecc6fb2ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Taxoids
72 rdf:type schema:DefinedTerm
73 N1216ff731e1f4f8ab541aae667c4cf5d schema:name Lorus Therapeutics Inc, Toronto, ON, USA
74 rdf:type schema:Organization
75 N16453f1839eb4681aaac8c7dc8f5bf62 schema:name Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA
76 rdf:type schema:Organization
77 N16a41c30b7164820b87e5db013f8631e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Prednisone
79 rdf:type schema:DefinedTerm
80 N16e745ccd7a14a709539a1d059cf811c rdf:first N08b8a65e9b5943e4ab202624cc7c86a1
81 rdf:rest N36e3dd0148fd4cb4aae06a841165cc32
82 N1d183e51f1be4ec0a58d2809aca04a7c schema:name Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA
83 rdf:type schema:Organization
84 N29c53d6ecce84f66b3966b6fcf6adbe9 schema:name Ottawa Regional Cancer Centre, Ottawa, ON, USA
85 rdf:type schema:Organization
86 N2b62b4d0b1b54b66b361003f98b4cfa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Humans
88 rdf:type schema:DefinedTerm
89 N2ffab99e33474f7a8e08f5ca3c8af3c1 schema:volumeNumber 67
90 rdf:type schema:PublicationVolume
91 N3059357ac45a4cc1870b13c9e4fd0291 schema:name Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA
92 rdf:type schema:Organization
93 N31c1385c33094776a9c1034e70c1e532 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Aged
95 rdf:type schema:DefinedTerm
96 N36e3dd0148fd4cb4aae06a841165cc32 rdf:first sg:person.01123742514.34
97 rdf:rest N877b919a47bb46b0a583c9071b3123c2
98 N37b8091e8e5e4308aecf961b3ad2acaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Prostatic Neoplasms
100 rdf:type schema:DefinedTerm
101 N3a63e465457d4f5e8ea49044cc1ea483 schema:name readcube_id
102 schema:value 85f03debb1265c2f8da6fcd723e1099d1b7df7557bce34ae0cbd597612af2b90
103 rdf:type schema:PropertyValue
104 N4ee1b3bf22fd46acaf4e3ffa81f61a0c rdf:first sg:person.01116377030.40
105 rdf:rest N6d7c5bf0ff4f4a4b8cb5baa6ce3c2793
106 N5441891e2cc74a0890b4b46ea5de1522 rdf:first sg:person.01142252161.65
107 rdf:rest N4ee1b3bf22fd46acaf4e3ffa81f61a0c
108 N5fc0afc42ca8459f900dfc2dd89d95a2 schema:issueNumber 4
109 rdf:type schema:PublicationIssue
110 N6821fbfbd3d446049e40cf37e776a200 schema:name BC Cancer Agency, Vancouver, BC, USA
111 rdf:type schema:Organization
112 N6d7c5bf0ff4f4a4b8cb5baa6ce3c2793 rdf:first sg:person.01236307062.83
113 rdf:rest N96102aa878a94eb2a4288033fed7f3a1
114 N6f89a799be0c4836bc33b3e997af5f7b schema:name dimensions_id
115 schema:value pub.1028116130
116 rdf:type schema:PropertyValue
117 N70d131a9378c4549b7caf66bfe76e425 schema:name Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, M5G 2M9, Toronto, ON, USA
118 rdf:type schema:Organization
119 N795ee06ba38e4844950042b45f9fcdbe schema:name London Regional Cancer Center, London, ON, USA
120 rdf:type schema:Organization
121 N7963cd531f7140219759201feee4ca9a schema:name nlm_unique_id
122 schema:value 7806519
123 rdf:type schema:PropertyValue
124 N8074b3cab8a3481f934733ce7cb45db6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Male
126 rdf:type schema:DefinedTerm
127 N820f16b9507b4f2b886e98797f4ca5a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Follow-Up Studies
129 rdf:type schema:DefinedTerm
130 N854763b9cc304424be726418ccac7040 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Orchiectomy
132 rdf:type schema:DefinedTerm
133 N8661d8c25d004bfca582457f3bf92ee0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Antineoplastic Combined Chemotherapy Protocols
135 rdf:type schema:DefinedTerm
136 N877b919a47bb46b0a583c9071b3123c2 rdf:first sg:person.07455026572.07
137 rdf:rest rdf:nil
138 N8b84f79f49ee44939c125df754ded6dd rdf:first sg:person.01204166657.51
139 rdf:rest N977cd0c53c544561bc49952c4b4bdaf7
140 N8d7242c954654bb3af756e5ed1cc51b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Leukocytes, Mononuclear
142 rdf:type schema:DefinedTerm
143 N95877e5418604f4a964b104e8bf968b2 schema:name Juravinski Cancer Center, Hamilton, ON, USA
144 rdf:type schema:Organization
145 N96102aa878a94eb2a4288033fed7f3a1 rdf:first sg:person.012667465007.49
146 rdf:rest N9ca6cdb5483a4998b281778e37316aa1
147 N977cd0c53c544561bc49952c4b4bdaf7 rdf:first sg:person.0617500177.29
148 rdf:rest N5441891e2cc74a0890b4b46ea5de1522
149 N9ca6cdb5483a4998b281778e37316aa1 rdf:first sg:person.0754450325.91
150 rdf:rest Nb9f48777b788454abab76d9c330a481a
151 Na2690eaec180498dba2e1b665df52e7c schema:name pubmed_id
152 schema:value 20602233
153 rdf:type schema:PropertyValue
154 Nb6db3871916844988f2f47be19bfd2d2 schema:name doi
155 schema:value 10.1007/s00280-010-1389-7
156 rdf:type schema:PropertyValue
157 Nb9f48777b788454abab76d9c330a481a rdf:first sg:person.01007474330.73
158 rdf:rest Ne694afb719a84767a9ea2e8dea88ee76
159 Nbad64eea7d8340d4994bb9db00891324 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Middle Aged
161 rdf:type schema:DefinedTerm
162 Nbc7eb85bcd4e4e6ba177e81d713263e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Prostate-Specific Antigen
164 rdf:type schema:DefinedTerm
165 Ne3964dcac4f744c895f1a8d33ffc2d29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Treatment Outcome
167 rdf:type schema:DefinedTerm
168 Ne694afb719a84767a9ea2e8dea88ee76 rdf:first sg:person.0760103773.19
169 rdf:rest N16e745ccd7a14a709539a1d059cf811c
170 Ne9bfdfc08bda4bc4be6b9b759eec0634 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Oligodeoxyribonucleotides
172 rdf:type schema:DefinedTerm
173 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
174 schema:name Medical and Health Sciences
175 rdf:type schema:DefinedTerm
176 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
177 schema:name Clinical Sciences
178 rdf:type schema:DefinedTerm
179 sg:grant.2426791 http://pending.schema.org/fundedItem sg:pub.10.1007/s00280-010-1389-7
180 rdf:type schema:MonetaryGrant
181 sg:journal.1088364 schema:issn 0344-5704
182 1432-0843
183 schema:name Cancer Chemotherapy and Pharmacology
184 rdf:type schema:Periodical
185 sg:person.01007474330.73 schema:affiliation https://www.grid.ac/institutes/grid.410425.6
186 schema:familyName Juhasz
187 schema:givenName Agnes
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007474330.73
189 rdf:type schema:Person
190 sg:person.01116377030.40 schema:affiliation N95877e5418604f4a964b104e8bf968b2
191 schema:familyName Hotte
192 schema:givenName Sebastien J.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116377030.40
194 rdf:type schema:Person
195 sg:person.01123742514.34 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
196 schema:familyName Zwiebel
197 schema:givenName James A.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123742514.34
199 rdf:type schema:Person
200 sg:person.01142252161.65 schema:affiliation N6821fbfbd3d446049e40cf37e776a200
201 schema:familyName Chi
202 schema:givenName Kim N.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65
204 rdf:type schema:Person
205 sg:person.01204166657.51 schema:affiliation N16453f1839eb4681aaac8c7dc8f5bf62
206 schema:familyName Sridhar
207 schema:givenName Srikala S.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204166657.51
209 rdf:type schema:Person
210 sg:person.01236307062.83 schema:affiliation N795ee06ba38e4844950042b45f9fcdbe
211 schema:familyName Ernst
212 schema:givenName Scott
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236307062.83
214 rdf:type schema:Person
215 sg:person.012667465007.49 schema:affiliation N3059357ac45a4cc1870b13c9e4fd0291
216 schema:familyName Wang
217 schema:givenName Lisa
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012667465007.49
219 rdf:type schema:Person
220 sg:person.0617500177.29 schema:affiliation N29c53d6ecce84f66b3966b6fcf6adbe9
221 schema:familyName Canil
222 schema:givenName Christina M.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617500177.29
224 rdf:type schema:Person
225 sg:person.07455026572.07 schema:affiliation N70d131a9378c4549b7caf66bfe76e425
226 schema:familyName Moore
227 schema:givenName Malcolm J.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07455026572.07
229 rdf:type schema:Person
230 sg:person.0754450325.91 schema:affiliation N1d183e51f1be4ec0a58d2809aca04a7c
231 schema:familyName Chen
232 schema:givenName Eric X.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754450325.91
234 rdf:type schema:Person
235 sg:person.0760103773.19 schema:affiliation https://www.grid.ac/institutes/grid.410425.6
236 schema:familyName Yen
237 schema:givenName Yun
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760103773.19
239 rdf:type schema:Person
240 sg:pub.10.1007/s00280-009-1163-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1011933531
241 https://doi.org/10.1007/s00280-009-1163-x
242 rdf:type schema:CreativeWork
243 https://app.dimensions.ai/details/publication/pub.1075013035 schema:CreativeWork
244 https://app.dimensions.ai/details/publication/pub.1075295406 schema:CreativeWork
245 https://app.dimensions.ai/details/publication/pub.1077265246 schema:CreativeWork
246 https://app.dimensions.ai/details/publication/pub.1083167129 schema:CreativeWork
247 https://app.dimensions.ai/details/publication/pub.1083251660 schema:CreativeWork
248 https://doi.org/10.1016/0197-2456(89)90015-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053744925
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1016/j.jchromb.2005.09.036 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015047150
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1021/bi00475a007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1055177617
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1023/a:1008332724977 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303222
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1056/nejmoa040720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029249997
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1056/nejmoa041318 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028543233
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1093/annonc/mdi178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050255200
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1115/icem2007-7291 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092859094
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1158/1078-0432.ccr-07-0944 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006922944
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1158/1078-0432.ccr-08-0109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031820808
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1200/jco.1999.17.11.3461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074545753
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1200/jco.2005.23.16_suppl.7253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079368204
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1200/jco.2010.28.18_suppl.lba4511 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083946811
275 rdf:type schema:CreativeWork
276 https://doi.org/10.3892/or.15.5.1299 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071530002
277 rdf:type schema:CreativeWork
278 https://www.grid.ac/institutes/grid.410425.6 schema:alternateName City Of Hope National Medical Center
279 schema:name City of Hope National Medical Centre, Duarte, CA, USA
280 rdf:type schema:Organization
281 https://www.grid.ac/institutes/grid.48336.3a schema:alternateName National Cancer Institute
282 schema:name Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
283 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...